Overall Fundamental outlook

|fundrankingplaceholder|
|techrankingplaceholder|

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Revenue projections:

Revenue projections for GLENMARK
Revenue projections for GLENMARK

Investors may be wary of Glenmark Pharmaceuticals Limited as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 29.686506
debtToEquity 12.776000
earningsGrowth 0.158000
revenueGrowth 0.151000
grossMargins 0.707090
operatingMargins 0.183380
trailingEps 37.630000
forwardEps 79.207700

Glenmark Pharmaceuticals Limited's Forward PE is at a healthy level, indicating that the stock price is well-positioned relative to its earnings. With the stock not being overvalued, there remains room for future growth, suggesting a balanced opportunity for investors seeking potential upside.
GLENMARK's low Debt-to-Equity ratio reflects that the company isn't heavily reliant on debt, reducing financial risk. This conservative approach suggests GLENMARK maintains a stable financial foundation, with greater flexibility to manage future growth or challenges without over-leverage concerns.
With earnings and revenue growth in positive territory, GLENMARK is projected to expand its business. This strong financial performance suggests the company will continue to grow, as increased profitability and sales drive future success.
GLENMARK's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for GLENMARK
Price projections for GLENMARK

GLENMARK's price has consistently hovered around the lower end of analysts' projections. This pattern may reflect concerns regarding the company's ability to achieve its anticipated growth.

Recommendation changes over time:

Recommendations trend for GLENMARK
Recommendations trend for GLENMARK


GLENMARK has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view GLENMARK as a reliable choice for their money, offering a promising avenue for future growth and financial gains.